Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020

Publisher Name :
Date: 30-Apr-2020
No. of pages: 503
Inquire Before Buying

Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 14, 30, 4, 95, 18 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).

- The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020

Table of Contents
Introduction
Idiopathic Pulmonary Fibrosis - Overview
Idiopathic Pulmonary Fibrosis - Therapeutics Development
Idiopathic Pulmonary Fibrosis - Therapeutics Assessment
Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development
Idiopathic Pulmonary Fibrosis - Drug Profiles
Idiopathic Pulmonary Fibrosis - Dormant Projects
Idiopathic Pulmonary Fibrosis - Discontinued Products
Idiopathic Pulmonary Fibrosis - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Products under Development by Companies, H1 2020 (Contd..8), H1 2020
Products under Development by Companies, H1 2020 (Contd..9), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Idiopathic Pulmonary Fibrosis - Pipeline by Abeome Corp, H1 2020
Idiopathic Pulmonary Fibrosis - Pipeline by Accendatech Au Pty Ltd, H1 2020
Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Ltd, H1 2020
Idiopathic Pulmonary Fibrosis - Pipeline by Afimmune Biopharma Ltd, H1 2020
Idiopathic Pulmonary Fibrosis - Pipeline by Algernon Pharmaceuticals Inc, H1 2020
Idiopathic Pulmonary Fibrosis - Pipeline by Altavant Sciences Inc, H1 2020
Idiopathic Pulmonary Fibrosis - Pipeline by Altay Therapeutics Inc, H1 2020
Idiopathic Pulmonary Fibrosis - Pipeline by Amgen Inc, H1 2020

List of Figures
Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
  • Global and United States Idiopathic Pulmonary Fibrosis Drug Market Report & Forecast 2022-2028
    Published: 12-May-2022        Price: US 4350 Onwards        Pages: 95
    Idiopathic Pulmonary Fibrosis Drug market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Idiopathic Pulmonary Fibrosis Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028. For United States market, this report focuses on the Idiop......
  • Global Pirfenidone Market Insights and Forecast to 2028
    Published: 07-Mar-2022        Price: US 4900 Onwards        Pages: 112
    Pirfenidone market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Pirfenidone market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028. Segment by Type - Tablet - Capsule - Other Segment by Application - Mild Idiopathic Pulmonary Fibrosis......
  • Global Pneumonia Therapeutics Market Insights and Forecast to 2028
    Published: 02-Mar-2022        Price: US 4900 Onwards        Pages: 94
    Pneumonia Therapeutics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Pneumonia Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028. Segment by Type - Vaccines - Anti-Infectives - Oxygen Therapy Segme......
  • Global Pirfenidone Market Research Report 2021 - Impact of COVID-19 on the Market
    Published: 22-Feb-2022        Price: US 3000 Onwards        Pages: 111
    The Pirfenidone market revenue was xx Million USD in 2016, grew to xx Million USD in 2021, and will reach xx Million USD in 2026, with a CAGR of xx during 2021-2026. Considering the influence of COVID-19 on the global Pirfenidone market, this report analyzed the impact from both global and regional perspectives. From production end to consumption end in regions such as North America, Europe, China, and Japan, the report put emphasis on analysis of market under COVID-19 and......
  • Global Idiopathic Pulmonary Fibrosis Drug Market Research Report 2021 - Impact of COVID-19 on the Market
    Published: 10-Feb-2022        Price: US 3000 Onwards        Pages: 100
    The Idiopathic Pulmonary Fibrosis Drug market revenue was xx Million USD in 2016, grew to xx Million USD in 2021, and will reach xx Million USD in 2026, with a CAGR of xx during 2021-2026. Considering the influence of COVID-19 on the global Idiopathic Pulmonary Fibrosis Drug market, this report analyzed the impact from both global and regional perspectives. From production end to consumption end in regions such as North America, Europe, China, and Japan, the report put emp......
  • Pneumonia Therapeutics Market - Global Outlook and Forecast 2022-2028
    Published: 21-Jan-2022        Price: US 3250 Onwards        Pages: 67
    Pneumonia is a respiratory disease characterized by inflammation of air sacs in lungs due to bacterial or viral infection. This report contains market size and forecasts of Pneumonia Therapeutics in Global, including the following market information: Global Pneumonia Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions) Global top five companies in 2021 (%) The global Pneumonia Therapeutics market was valued at 12350 million in 2021 and is projected to......
  • Global Pirfenidone Market Growth 2022-2028
    Published: 19-Jan-2022        Price: US 3660 Onwards        Pages: 105
    As the global economy mends, the 2021 growth of Pirfenidone will have significant change from previous year. According to our (LP Information) latest study, the global Pirfenidone market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Pirfenidone market size will reach USD million in 2028, growing at a CAGR of % over the analysis period. The United States Pirfenidone market is expected at value of US$ million in 2021 and grow......
  • Global Idiopathic Pulmonary Fibrosis Drug Market Growth 2022-2028
    Published: 14-Jan-2022        Price: US 3660 Onwards        Pages: 91
    As the global economy mends, the 2021 growth of Idiopathic Pulmonary Fibrosis Drug will have significant change from previous year. According to our (LP Information) latest study, the global Idiopathic Pulmonary Fibrosis Drug market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Idiopathic Pulmonary Fibrosis Drug market size will reach USD million in 2028, growing at a CAGR of % over the analysis period. The United States Idi......
  • Global Idiopathic Pulmonary Fibrosis Drug Market Insights and Forecast to 2028
    Published: 14-Jan-2022        Price: US 4900 Onwards        Pages: 90
    Idiopathic Pulmonary Fibrosis Drug market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Idiopathic Pulmonary Fibrosis Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028. Segment by Type - Glucocorticoid - Immunosuppressive Agent - Others ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs